No abstract

No abstract

G-CSF mobilized PBSCs are increasingly used in allo-SCT due to their relative ease of collection 1 and because higher CD34 þ cell doses may be associated with improved transplant outcomes in some settings.2,3 However, some healthy donors may show poor mobilization response to G-CSF and poor subsequent CD34 þ apheresis yields. 4,5 Therefore, identifying donors at risk for poor mobilization and a reliable estimate of a healthy donor's CD34 þ cell mobilization response to G-CSF and subsequent CD34 þ cells yield could be of value in optimizing transplantation approaches. The aim of this single center report was to analyze factors associated with the total CD34 þ PBSC yield in an ethnically homogeneous Caucasian population of 95 healthy allogeneic adult donors.All donors received G-CSF dosed at 10 mg/kg/day (Filgrastim, Amgen, France) for 5 days followed by leukapheresis. Complete blood counts (total WBC, Hb, Plts) were measured for all donors at baseline before G-CSF administration, before and after PBSC collection. Peripheral blood CD34 þ cell counts were also measured before apheresis. Sixty-nine donors (73%) were healthy sibling donors, whereas 26 (27%) were healthy volunteer donors for HLA-identical unrelated transplants. All donors were undergoing their first PBSC mobilization (study period 2004-2008

Our study shows strong differences in terms of quantitative and qualitative cellular composition between several blood or graft sources, possibly explaining the differences observed in terms of outcomes after transplant.